Supriya Lifescience (SUPRIYA) Panoramica del titolo
Supriya Lifescience Limited si occupa di ricerca e sviluppo, produzione e vendita di farmaci sfusi e prodotti chimici farmaceutici in tutto il mondo. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 2/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per SUPRIYA dai nostri controlli di rischio.
SUPRIYA Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Supriya Lifescience Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | ₹917.45 |
| Massimo di 52 settimane | ₹1,085.00 |
| Minimo di 52 settimane | ₹545.50 |
| Beta | 0.65 |
| Variazione di 1 mese | 7.81% |
| Variazione a 3 mesi | -6.11% |
| Variazione di 1 anno | 40.39% |
| Variazione a 3 anni | 213.50% |
| Variazione a 5 anni | n/a |
| Variazione dall'IPO | 134.73% |
Notizie e aggiornamenti recenti
Recent updates
Aggiornamento narrativa • Jun 16
SUPRIYA: USFDA VAI Outcome And Exports Will Shape Balanced Stock Outlook
Analysts have maintained their price target for Supriya Lifescience at ₹940, reflecting unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News for Supriya Lifescience Supriya Lifescience has scheduled a board meeting on May 27, 2026, to consider and approve audited financial results for the quarter and financial year ended March 31, 2026, and to consider a dividend on equity shares for the same period.Aggiornamento narrativa • Jun 02
SUPRIYA: USFDA VAI Outcome Will Signal Downside Risk To Export Reliance
Analysts have maintained their price target for Supriya Lifescience at ₹940. The steady figure reflects updated assumptions of lower revenue growth, slightly higher profit margins, and a marginally reduced future P/E outlook.Articolo di analisi • May 23
With EPS Growth And More, Supriya Lifescience (NSE:SUPRIYA) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Aggiornamento narrativa • May 10
SUPRIYA: USFDA VAI Outcome Will Drive April 2026 Board Decisions
Analysts have kept Supriya Lifescience's fair value estimate steady at ₹940, indicating that recent tweaks to assumptions such as the discount rate and future P/E are seen as refinements rather than drivers of a changed price target. What's in the News USFDA issued an Establishment Inspection Report with a Voluntary Action Indicated classification for Supriya Lifescience's API facility at Lote Parshuram, Maharashtra, closing the February 2 to February 6, 2026 inspection cycle and confirming ongoing cGMP compliance (Regulatory filing).Aggiornamento narrativa • Apr 26
SUPRIYA: Bullish View Will Center On April 2026 Board And Director Decisions
Analysts have kept their price target for Supriya Lifescience steady at ₹940, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E expectations. What's in the News A special or extraordinary shareholders meeting is scheduled for April 10, 2026 via postal ballot in India to consider appointing Mr. Manish Panchal as a non executive independent director for a five year term from February 9, 2026 to February 8, 2031 (Key Developments).Aggiornamento narrativa • Apr 08
SUPRIYA: Bullish View Will Focus On April 2026 Shareholder Decisions
Analysts have kept Supriya Lifescience's fair value estimate steady at ₹940. This reflects unchanged views on its discount rate, revenue growth outlook, profit margin expectations and future P/E assumptions.Aggiornamento narrativa • Mar 25
SUPRIYA: Bullish View Will Await April 2026 Shareholder Meeting Outcome
Analysts are maintaining their fair value estimate for Supriya Lifescience at ₹940 per share. This reflects unchanged assumptions on discount rate, revenue growth, profit margin and future P/E, which together support a steady view on the company’s valuation outlook.Aggiornamento narrativa • Mar 11
SUPRIYA: Bullish View Will Await February 2026 Results As Key Catalyst
Analysts have kept their price target for Supriya Lifescience steady at ₹940, reflecting unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The board has scheduled a meeting for Feb 09, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Aggiornamento narrativa • Feb 24
SUPRIYA: Steady Thesis Will Rely On Upcoming February 2026 Results Catalyst
Analysts have kept their fair value estimate for Supriya Lifescience steady at ₹940. They explain the unchanged price target by relatively similar assumptions on revenue growth, profit margins and future P/E compared with their prior model.Aggiornamento narrativa • Feb 10
SUPRIYA: Future Returns Will Reflect Steady Thesis And Upcoming Results Catalyst
Analysts have kept their fair value estimate for Supriya Lifescience steady at ₹940.0, with the latest tweak in assumptions mainly reflecting a slightly adjusted discount rate and future P/E expectations rather than a change in the underlying thesis. What's in the News A board meeting is scheduled for February 9, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Articolo di analisi • Jan 29
Supriya Lifescience Limited's (NSE:SUPRIYA) Business Is Yet to Catch Up With Its Share Price
With a price-to-earnings (or "P/E") ratio of 29.2x Supriya Lifescience Limited ( NSE:SUPRIYA ) may be sending bearish...Aggiornamento narrativa • Jan 26
SUPRIYA: Future Returns Will Reflect Higher P E Expectations And Earnings Visibility
Analysts have lifted their fair value estimate for Supriya Lifescience from ₹850 to ₹940, citing updated assumptions around future P/E levels while keeping growth, margins and the discount rate broadly unchanged. What's in the News Board meeting scheduled for Nov 12, 2025, at 15:00 Indian Standard Time to consider and approve unaudited financial results for the quarter and half year ended Sep 30, 2025, along with the statutory auditors' limited review report (company filing).Aggiornamento narrativa • Jan 10
SUPRIYA: Future Returns Will Reflect Stable Board Oversight And Dividend Confidence
Analysts have maintained their fair value estimate for Supriya Lifescience at ₹850.0. This reflects unchanged views on discount rate, revenue growth, profit margin and future P/E assumptions that continue to support this target. What's in the News Board meeting scheduled for November 12, 2025, at 15:00 Indian Standard Time, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2025 (Key Developments).Aggiornamento narrativa • Dec 17
SUPRIYA: Future Returns Will Reflect WHO GMP Certification And Dividend Confidence
Analysts have maintained their price target for Supriya Lifescience at ₹850.00 per share, citing stable assumptions on the discount rate, revenue growth, profit margins, and future valuation multiples as justification for keeping their outlook unchanged. What's in the News World Health Organisation grants WHO GMP certification for inhalation dosages at Supriya Lifescience's Ambernath facility, enabling production, sale, and wider global distribution from the site (Regulatory filing).Aggiornamento narrativa • Dec 03
SUPRIYA: Future Returns Will Reflect WHO GMP Certification-Driven Expansion
Analysts have modestly reiterated their conviction in Supriya Lifescience with an unchanged fair value estimate of ₹850.00 per share, reflecting stable assumptions on growth, profitability, and valuation multiples. What's in the News The World Health Organization has granted WHO GMP certification for Supriya Lifescience’s Ambernath facility for inhalation dosages, enabling production, sale, and wider global distribution from the site (Regulatory filing).Aggiornamento narrativa • Nov 19
SUPRIYA: Future Performance To Reflect Improved Margins And WHO-GMP Certification
Analysts have raised their price target for Supriya Lifescience from ₹800 to ₹850, citing stronger revenue growth projections and improved profit margins. What's in the News The board meeting is scheduled for November 12, 2025 to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025.Aggiornamento narrativa • Aug 23
Expansion Into Regulated Markets And CMO/CDMO Opportunities To Strengthen Future Prospects
Despite a substantial increase in consensus revenue growth forecasts and a notable reduction in future P/E, analysts have revised Supriya Lifescience’s fair value down from ₹843 to ₹800. What's in the News Board meeting scheduled to approve unaudited financial results for the quarter ended June 30, 2025.Articolo di analisi • Jul 03
Supriya Lifescience Limited's (NSE:SUPRIYA) Shareholders Might Be Looking For Exit
It's not a stretch to say that Supriya Lifescience Limited's ( NSE:SUPRIYA ) price-to-earnings (or "P/E") ratio of...Articolo di analisi • Apr 04
Here's Why We Think Supriya Lifescience (NSE:SUPRIYA) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Articolo di analisi • Mar 04
Subdued Growth No Barrier To Supriya Lifescience Limited's (NSE:SUPRIYA) Price
It's not a stretch to say that Supriya Lifescience Limited's ( NSE:SUPRIYA ) price-to-earnings (or "P/E") ratio of...
Nuova narrativa • Feb 11
Expansion Into High-Margin Therapeutic Segments Like Anti-Stimulants Will Strengthen Future Prospects
Expanding into high-margin therapeutic segments and increasing exports highlight Supriya Lifescience's potential for robust future revenue growth.Articolo di analisi • Nov 07
Supriya Lifescience Limited (NSE:SUPRIYA) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Supriya Lifescience Limited ( NSE:SUPRIYA ) shares have continued their recent momentum with a 26% gain in the last...Articolo di analisi • Sep 08
Supriya Lifescience (NSE:SUPRIYA) Has Announced That It Will Be Increasing Its Dividend To ₹0.80
The board of Supriya Lifescience Limited ( NSE:SUPRIYA ) has announced that it will be paying its dividend of ₹0.80 on...Articolo di analisi • Jun 05
We Think You Should Be Aware Of Some Concerning Factors In Supriya Lifescience's (NSE:SUPRIYA) Earnings
Supriya Lifescience Limited's ( NSE:SUPRIYA ) healthy profit numbers didn't contain any surprises for investors...Articolo di analisi • May 10
Little Excitement Around Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings
With a price-to-earnings (or "P/E") ratio of 24.6x Supriya Lifescience Limited ( NSE:SUPRIYA ) may be sending bullish...Articolo di analisi • Feb 09
Lacklustre Performance Is Driving Supriya Lifescience Limited's (NSE:SUPRIYA) Low P/E
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 33x, you may consider...Articolo di analisi • May 28
Supriya Lifescience's (NSE:SUPRIYA) Shareholders May Want To Dig Deeper Than Statutory Profit
The recent earnings posted by Supriya Lifescience Limited ( NSE:SUPRIYA ) were solid, but the stock didn't move as much...Rendimenti per gli azionisti
| SUPRIYA | IN Pharmaceuticals | IN Mercato | |
|---|---|---|---|
| 7D | 8.9% | -0.4% | -0.6% |
| 1Y | 40.4% | 15.5% | -0.1% |
Ritorno vs Industria: SUPRIYA ha superato il Indian Pharmaceuticals che ha restituito 15.5 % nell'ultimo anno.
Rendimento vs Mercato: SUPRIYA ha superato il mercato Indian che ha restituito -0.1 % nell'ultimo anno.
Volatilità dei prezzi
| SUPRIYA volatility | |
|---|---|
| SUPRIYA Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 3.4% |
Prezzo delle azioni stabile: SUPRIYA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di SUPRIYA è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1987 | 607 | Saloni Wagh | www.supriyalifescience.com |
Supriya Lifescience Limited si occupa di ricerca e sviluppo, produzione e vendita di farmaci sfusi e prodotti chimici farmaceutici in tutto il mondo. L'azienda offre ingredienti farmaceutici attivi nei settori antistaminico, antiallergico, antiasmatico, decongestionante, analgesico/antipiretico/anestetico, antipertensivo, antimalarico, vitamine, antimalarico e antigotta. Fornisce anche prodotti oncologici, veterinari e di categoria generale.
Supriya Lifescience Limited Riepilogo dei fondamenti
| SUPRIYA statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | ₹73.35b |
| Utili (TTM) | ₹1.98b |
| Ricavi(TTM) | ₹8.73b |
37.2x
Rapporto P/E8.5x
Rapporto P/SSUPRIYA è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| SUPRIYA Conto economico (TTM) | |
|---|---|
| Ricavi | ₹8.73b |
| Costo del fatturato | ₹2.79b |
| Profitto lordo | ₹5.94b |
| Altre spese | ₹3.96b |
| Utili | ₹1.98b |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 24.65 |
| Margine lordo | 68.06% |
| Margine di profitto netto | 22.74% |
| Rapporto debito/patrimonio netto | 0.5% |
Come si è comportato SUPRIYA nel lungo periodo?
Vedi performance storica e confrontoDividendi
0.1%
Rendimento attuale del dividendo4%
Rapporto di remunerazioneSUPRIYA paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di SUPRIYA| Supriya Lifescience date dei dividendi | |
|---|---|
| Data di stacco del dividendo | Sep 04 2026 |
| Data di pagamento dei dividendi | Oct 24 2026 |
| Giorni fino al dividendo Ex | 7 days |
| Giorni prima della data di pagamento dei dividendi | 43 days |
SUPRIYA paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di SUPRIYAAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/10 12:54 |
| Prezzo dell'azione a fine giornata | 2026/09/10 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Supriya Lifescience Limited è coperta da 2 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Maitri Sheth | Choice Equity Broking Private Limited |
| null null | K.R. Choksey Shares & Securities Private Ltd. |